Skip to main content

Table 3 Cerebrospinal fluid biomarker data in all groups

From: The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias

  

NfL (pg/ml)

Median (IQR)

t-taua (pg/ml)

Median (IQR)

p-taub (pg/ml)

Median (IQR)

Aβ42c (pg/ml)

Median (IQR)

t-tau/p-tau

Median (IQR)

NfL/p-tau

Median (IQR)

14-3-3 (positive)

Prion disease

Typical (n = 82)

15,000 (9254–24,425)

7048 (3549–10,550)

60 (47–75)

646 (420–811)

121.60 (66.18–194.90)

257.89 (177.94–402.00)

82/82

Atypical (n = 59)

9139 (5234–17,000)

1546 (933–2221)

44 (34–63)

527 (372–771)

33.57 (21.43–54.91)

215.98 (125.26–425.00)

21/59

Total prion disease (n = 141)

12,300 (7160–22,650)

3103 (1803–8555)

51 (40–71)

620 (399–780)

66.94 (33.57–152.67)

247.29 (156.02–404.71)

103/141

AD

Typical (n = 36)

1933 (1515–2788)

572 (424–817)

80 (67–105)

363 (277–437)

7.09 (6.11–7.80)

23.55 (18.48–30.27)

0/36

Atypical (n = 37)

2521 (1662–3330)

1115 (772–1631)

123 (102–153)

352 (257–508)

8.90 (7.85–10.32)

17.39 (12.86–28.85)

4/37

Total AD (n = 73)

2033 (1592–3067)

822 (565–1186)

106 (74–143)

358 (268–465)

7.84 (6.71–9.72)

20.30 (14.85–29.77)

4/73

DLB

Typical (n = 24)

1857 (1398–2682)

268 (125–395)

42 (34–54)

647 (334–912)

5.63 (4.76–7.18)

41.85 (30.39–61.69)

0/22

Atypical (n = 11)

4207 (1633–29,500)

713 (230–1374)

51 (31–112)

360 (179–559)

7.43 (5.10–19.91)

88.91 (19.10–573.97)

3/10

Total DLB (n = 35)

2171 (1414–4007)

275 (160–438)

42 (33–61)

476 (303–722)

6.20 (4.89–8.18)

42.34 (28.68–94.20)

3/32

FTLD

Typical (n = 35)

3191 (1910–4963)

217 (154–378)

38 (27–53)

711 (570–928)

6.12 (4.40–7.91)

78.00 (40.13–158.08)

0/31

Atypical (n = 9)

6785 (3785–12,500)

341 (198–849)

45 (31–52)

708 (372–877)

7.80 (6.02–10.42)

153.54 (72.90–364.83)

1/9

Total FTLD (n = 44)

3628 (2308–6647)

245 (173–407)

41 (28–53)

709 (546–920)

6.52 (4.76–9.02)

86.06 (43.11–197.90)

1/40

bvFTD (n = 19)

3729 (1910–11,900)

204 (150–380)

35 (26–44)

717 (519–922)

6.52 (4.69–7.80)

153.54 (41.24–304.65)

1/17

PPA (n = 6)

5626 (2768–8173)

393 (177–637)

47 (34–62)

928 (744–1214)

7.78 (5.83–10.71)

109.11 (63.12–177.75)

0/6

Tauopathies (CBS + PSP) (n = 19)

2733 (2459–3940)

244 (177–373)

45 (28–57)

619 (452–785)

6.54 (4.30–8.13)

60.73 (40.13–138.74)

0/17

Control subjects

Total (n = 30)

1167 (805–1543)

164 (136–255)

38 (30–46)

815 (642–1045)

5.43 (4.06–6.20)

33.00 2(20.22–44.26)

NA

  1. Abbreviations: Aβ42 β-Amyloid 42, AD Alzheimer’s disease, bvFTD Behavioral variant of frontotemporal dementia, CBS Corticobasal syndrome; DLB Dementia with Lewy bodies, FTLD Frontotemporal lobar degeneration, NA Not available, NfL Neurofilament light chain protein, PPA Primary progressive aphasia, PSP Progressive supranuclear palsy, p-tau Phosphorylated tau protein, t-tau Total tau protein
  2. aPrion disease vs. control subjects (p < 0.001); prion disease vs. each ND group (p < 0.001); AD vs. control subjects (p < 0.001); AD vs. each ND group (p < 0.001)
  3. bAD vs. prion disease (p < 0.001); prion disease vs. FTLD (p < 0.001); prion disease vs. bvFTD (p < 0.001); AD vs. FTLD (p < 0.001); AD vs. bvFTD or PPA or tauopathies (p < 0.001)
  4. cPrion disease vs. AD (p < 0.001); FTLD vs. DLB (p = 0.018); DLB vs. PPA (p = 0.004); AD vs. FTLD (p < 0.001); AD vs. bvFTD or PPA or tauopathies (p < 0.001); AD vs. DLB (p = 0.024)
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193